Download PDF
Thromb Haemost 1992; 68(05): 495-499
DOI: 10.1055/s-0038-1646306
Original Article
Schattauer GmbH Stuttgart

Prolonged Bleeding Time in Patients with Lupus Anticoagulant

E Orlando
The Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
,
S Cortelazzo
The Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
,
M Marchetti
The Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
,
R Sanfratello
The Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
,
T Barbui
The Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
› Author Affiliations
Further Information

Publication History

Received 23 January 1992

Accepted after revision 10 June 1992

Publication Date:
04 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Platelet adhesion to collagen under flow conditions was studied in 18 patients with lupus anticoagulant, seven of which showed a prolonged bleeding time in the presence of a normal platelet count. The effect of patient plasma, IgG and purified anticardiolipin antibodies on platelet adhesion was also examined. We found a significant reduction of platelet adhesion in patients with lupus anticoagulant, which was more evident in patients with prolonged bleeding time. This platelet adhesion defect could be attributed to a plasma factor. In fact, patients' platelets regained normal adhesion when mixed with normal plasma, whereas controls' platelets showed abnormal adhesion in the presence of patient plasma. A causative role of antiphospholipid antibodies was demonstrated in experiments using purified immunoglobulins and anticardiolipin antibodies.

 

  • REFERENCES

  • 1 Much JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980; 92: 156-160
    CrossrefPubMedGoogle Scholar
  • 2 Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9
    PubMedGoogle Scholar
  • 3 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticar-diolipin antibodies (ACA), directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
    CrossrefPubMedGoogle Scholar
  • 4 Bevers EM, Comfurius P, van Rijn JLML, Hemker HC, Zwaal RFA. Generation of prothrombin converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem 1982; 122: 429-436
    CrossrefPubMedGoogle Scholar
  • 5 Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, Hughes GRV. Thrombocytopenia in SLE and related autoimmune disorders - Association with anticardiolipin antibodies. Br J Haematol 1985; 59: 227-230
    CrossrefPubMedGoogle Scholar
  • 6 Coehn AJ, Philips TM, Kessler CM. Circulating coagulation inhibitors in the Acquired Immunodeficiency Syndrome. Ann Intern Med 1986; 104: 175-180
    CrossrefPubMedGoogle Scholar
  • 7 Galli M, Béguin S, Lindhout T, Hemker CH. Inhibition of phospholipid and platelet-dependent prothrombinase activity in the plasma of patients with lupus anticoagulant. Br J Haematol 1989; 72: 549-555
    CrossrefPubMedGoogle Scholar
  • 8 Galli M, Cortelazzo S, Viero P, Finazzi G, de Gaetano G, Barbui T. Interaction between platelets and lupus anticoagulant. Eur J Haematol 1988; 41: 88-94
    PubMedGoogle Scholar
  • 9 Exner T, Rickard A, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-151
    CrossrefPubMedGoogle Scholar
  • 10 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russel viper venom time for the diagnosis of lupus anticoagulant. Blood 1986; 68: 869-874
    PubMedGoogle Scholar
  • 11 Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemostas 1991; 65: 320-322
    PubMedGoogle Scholar
  • 12 Loizou S, McCrea JD, Rudge A, Reynolds R, Boyle CE, Harris EN. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunoadsorbent assay (ELISA): standardization and quantification of results. Clin Exp Immunol 1985; 62: 738-744
    PubMedGoogle Scholar
  • 13 Pengo V, Thiagarajan P, Shapiro SS, Hein MJ. Immunological specificity and mechanism of action of IgG lupus anticoagulant. Blood 1987; 70: 69-76
    PubMedGoogle Scholar
  • 14 Sakariassen KB, Bolhuis PA, Sixma JJ. Adhesion of human blood platelets to human artery subendothelium is mediated by factor VIII-von Willebrand factor bound to subendothelium. Nature 1979; 279: 636-638
    CrossrefPubMedGoogle Scholar
  • 15 Sakariassen KS, Aarts PAMM, de Groot PG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 1983; 102: 522-535
    PubMedGoogle Scholar
  • 16 Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973; 5: 167-179
    CrossrefPubMedGoogle Scholar
  • 17 Zwaginga JJ, Sixma JJ, de Groot PG. Activation of endothelial cells induces platelet thrombus formation on their matrix. Arteriosclerosis 1990; 10: 49-61
    CrossrefPubMedGoogle Scholar
  • 18 Lechner K. Lupus anticoagulant and thrombosis. In: Thrombosis and Haemostasis 1987. Verstraete M, Vermylen J, Lijnen HR, Arnout J. (eds) International Society on Thrombosis and Haemostasis and. Leuven University Press, Leuven: 1987. p 525
    Google Scholar
  • 19 Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJW. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol 1985; 19: 265-275
    CrossrefPubMedGoogle Scholar
  • 20 Hasselaar P, Derksen RHWM, Blokzijl L, Hessing M, Nieuwenhuis HK, Bouma BN, de Groot PG. Risk factors for thrombosis in lupus patients. Ann Rheum Dis 1989; 48: 933-940
    CrossrefPubMedGoogle Scholar